Randomized Trial of Treatments for Convergence Insufficiency

July 3, 2006 updated by: Pennsylvania College of Optometry

A Randomized Clinical Trial of Pencil Push-Ups Versus Office Based Vision Therapy For the Treatment of Convergence Insufficiency

The Convergence Insufficiency Treatment Trial (CITT) is a multi-center, placebo-controlled, single-masked, clinical trial designed to compare the benefits of two commonly used treatment approaches for patients with convergence insufficiency (CI)

Study Overview

Detailed Description

Considerable controversy exists regarding the best treatment for convergence insufficiency (CI), a common condition that often interferes with the ability to perform near work. The two most widely used treatments have significant differences in costs and in practitioner perceived utility. Pencil push-up therapy (PPT) is a simple, low-cost treatment in which patients are prescribed a single procedure to perform at home with only periodic follow-up. Office-based vision therapy (OBVT) is a more comprehensive, time-consuming, complex, and costly treatment in which patients are scheduled for weekly in-office therapy visits and are often prescribed a specific sequence of therapeutic procedures to perform at home. It is important to consider whether either, neither, or both treatments are effective.

The Convergence Insufficiency Treatment Trial (CITT) is a prospective, masked-examiner, multi-center clinical trial in which patients are randomized to one of these two treatment approaches. The primary goal is to answer the following question:

After 12 weeks of treatment, is one therapy more effective than the other in improving CI signs and symptoms? We will test the null hypothesis that there is no difference in the distribution of outcomes between the two populations.

The primary outcome measure will be a classification of each patient as a "success," "improvement," or "failure." This classification will be based on the level of improvement in both the signs (near point of convergence and positive fusional vergence) and symptoms of CI.

Additional questions relate to longer term effects:

  1. Are the patients who were classified as "success" or "improvement" at twelve weeks the same at the one-year follow-up for each treatment group?
  2. Are there differences in the distributions of changes in near point of convergence, positive fusional vergence, or accommodative amplitudes, between the two treatment groups, at twelve weeks and at one-year of follow up?

Study Type

Interventional

Enrollment

90

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Fullerton, California, United States, 92831
        • Southern California College of Optometry
    • New York
      • New York, New York, United States, 10036
        • State University of New York, College of Optometry
    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State University
      • Columbus, Ohio, United States, 43210
        • The Ohio State University, Optometry Coordinating Center
    • Oregon
      • Forest Grove, Oregon, United States, 97116
        • Pacific University College of Optometry
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19141
        • Eye Institute, Pennsylvania College of Optometry
    • Texas
      • Houston, Texas, United States, 77204
        • University of Houston, College of Optometry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 28 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 9-30 years
  • Best corrected visual acuity of 20/25 in both eyes at distance and near
  • Willingness to wear eyeglasses or contact lenses to correct refractive error, if necessary
  • Exophoria at near at least 4 prism diopters greater than at far
  • Insufficient positive fusional convergence (i.e., failing Sheard's criterion or minimum normative positive fusional vergence (PFV) of 15 base-out break).
  • Receded near point of convergence of > 6 cm break.
  • Normal random dot stereopsis using a 500 seconds of arc target.
  • CI Symptom Survey score > 16 for subjects in 9-18 year age range and > 21 for subjects in the 19-30 year age range.
  • Informed consent and willingness to participate in the study and be randomized

Exclusion Criteria:

  • CI previously treated with pencil push-ups (no more than 2 months of treatment within the past year)
  • CI previously treated with office-based vision therapy/orthoptics (no more than 2 months of treatment within the past year)
  • Amblyopia
  • Constant strabismus
  • History of strabismus surgery
  • Anisometropia >1.50D difference between eyes
  • Prior refractive surgery
  • Vertical heterophoria greater than 1 
  • Systemic diseases known to affect accommodation, vergence, and ocular motility such as: multiple sclerosis, Graves's thyroid disease, myasthenia gravis, diabetes, and Parkinson disease
  • Any ocular or systemic medication known to affect accommodation or vergence
  • Monocular accommodative amplitude less than 4 D in either eye as measured by the Donder's push-up method
  • Manifest or latent nystagmus
  • Attention deficit hyperactivity disorder (ADHD) or learning disability diagnosis by parental report
  • Household member or sibling already enrolled in the CITT
  • Any eye care professional, technician, medical student, or optometry student

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure
The primary outcome measure is the score on the Convergence Insufficiency Symptom Survey

Secondary Outcome Measures

Outcome Measure
Near Point of Convergence
Positive Fusional Vergence at Near

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Mitchell Scheiman, OD, Pennsylvania College of Optometry

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2000

Study Completion

November 1, 2001

Study Registration Dates

First Submitted

July 3, 2006

First Submitted That Met QC Criteria

July 3, 2006

First Posted (Estimate)

July 4, 2006

Study Record Updates

Last Update Posted (Estimate)

July 4, 2006

Last Update Submitted That Met QC Criteria

July 3, 2006

Last Verified

January 1, 2002

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Convergence Insufficiency

Clinical Trials on Pencil Push-ups

3
Subscribe